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PART A: ABSTRACT AND STUDY PROTOCOL 
  
ABSTRACT: 
Objective: To compare the efficacy of treatment modalities in patients with stage IB2 cervical 
cancer treated at Groote Schuur Hospital, Cape Town, South Africa. 
Materials and methods: This was a retrospective observational study of patients with stage 
IB2 cervical cancer treated from 1993-2008 with either primary radiation therapy (RT), with 
or without follow-on hysterectomy, or primary surgery (with or without adjuvant RT). 
Weekly cisplatin given concurrently with RT was used since 2003. Patient outcomes and 
grade 3-4 treatment-related toxicities were recorded.  
Results: The study included 78 eligible patients for whom the 5-year overall survival rate was 
70.8%. Overall 5-year survival rate by treatment modality was 88% for the 25 patients in the 
surgery group and 62.5% for the 53 patients in the RT group, respectively.  There was a 
marked difference in the proportion of patients in each group receiving additional therapy: 
88% of patients in the primary surgery group had adjuvant RT, while only 5.7% of patients in 
the primary RT group went on to have a hysterectomy. Grade 3-4 toxicity was found in 
13.2% of the RT versus 4% for the surgery group (p=0.4).  
Conclusion: The optimal primary treatment for stage IB2 cervical cancer remains unclear. 
Both types of primary treatments were found to be feasible therapeutic approaches. Primary 
surgery appears to have better survival outcomes at our institution. Selection bias and 
inadequate concurrent chemotherapy in 58% of patients receiving primary RT may account 
for the difference in survival.  
The number of patients in the surgery group requiring “bimodal” adjuvant treatment has cost 
implications in our resource-constrained environment, hence primary concurrent chemo-
radiation is being increasingly utilized for stage IB2 cervical cancer at our institution. 
Evidence from a randomized controlled study is needed to determine the optimal treatment 
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MMED PROTOCOL 
Title of Project: 
A retrospective study of patients with Stage 1B2 cervical cancer treated at Groote Schuur 
Hospital 1993-2008 
Research Question: 
Are there differences in outcome with patients with stage 1B2 cervical cancer treated with 
radical radiation/chemo-radiation versus radical surgery as primary modality for patients at 
Groote Schuur Hospital in Cape Town, South Africa, during the years 1993-2008? 
Aim of the Study: 
To establish by means of a retrospective audit the comparison between outcomes for patients
with cervical cancer stage 1B2 who were treated either with surgery or with chemo-radiation




 Monitoring of Grade 3 or 4 toxicities.
Materials and Methods: 
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Inclusion criteria for the study are: 
 Patients with histologically proven squamous carcinoma, adenocarcinoma or
adenosquamous carcinoma of cervix.
 Stage IB2 cancers (based on the FIGO sub-staging for stage IB cervical cancer
introduced in 1988).
Exclusion criteria for the study are: 
 Patients in the primary radiation (or chemo-radiation) group who have received an
external beam dose to the whole pelvis of less than 45 Gray (LQED2).
 Patients in the primary surgery group who had surgery less than a radical
hysterectomy and no pelvic lymphadenectomy.
 Small cell cancer of the cervix.
 Patients who have not received brachytherapy.
 Patients lost to follow-up less than one year after completion of primary treatment.
Patients will be selected from a departmental gynaecological clinical database. Data will be
extracted from this database and supplemented from individual patient folders. Direct patient
contact is not a requirement for this study.
Patients were assessed by a combined (multi-disciplinary) team where the initial staging 
assessment was done. The decision as to the primary treatment was made by the multi-
disciplinary team and in making that decision, factors such as patient age, co-morbidities,
performance status and extent of disease were taken into consideration.
Patients treated with surgery as their primary treatment had post-operative pathological 
review to determine whether the risk of microscopic residual disease warranted adjuvant 
treatment (radiation, chemotherapy or both). The risk factors considered were primary 
tumour size, depth of stromal invasion, presence of lymph node metastases, adequacy of 
resection lines, lympho-vascular space invasion (LVSI) and /or microscopic parametrial 
involvement.  
Similarly, patients with primary (chemo-) radiation therapy were assessed after 2-3 months 
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hysterectomy as part of the primary treatment course. This ‘salvage’ surgery must be done 
within four months of the completion date of chemo-RT to be considered as part of the 
primary treatment. Evidence of disease found after this period was assessed as loco-regional 
recurrence (with or without distant metastases). 
Surgical intervention involved radical (Wertheim’s) hysterectomy and pelvic lymph node 
dissection. The ovaries were preserved in premenopausal patients. 
Radiation therapy involved either: 
- Primary radiation (or concurrent chemo-radiation (CRT) with weekly cisplatin at a 
dose of 40mg/m², capped at 60 mg per dose). External beam radiotherapy (EBRT) 
doses varied over the study period but exceeded 45 Gy. Intracavitary therapy (ICT) 
with Iridium high dose-rate after-loading brachytherapy was incorporated in the latter 
half of the EBRT course. 
 
- Adjuvant whole pelvic RT (or CRT with weekly cisplatin) following primary surgery, 
as part of the primary treatment course. In selected cases, a “reduced pelvic volume” 
was used, depending on the individual risk factors for recurrence. In some cases, 
vaginal ICT was added. 
 
Treatment related morbidity (RTOG grades 3-4) will also be recorded and evaluated for each 
primary treatment group to better assess the respective “therapeutic ratio” of the two 
approaches.  
A spreadsheet containing all the relevant data points will be generated. Treatment outcomes 
and toxicity scores will be grouped according to the primary therapy and compared with the 
log-rank test. Of additional interest would be the proportion of patients in each of the two 
treatment approaches who undergo “double treatment”; in other words, requiring adjuvant RT 
after primary surgery, or surgery after primary RT, respectively.  
A discussion of the findings will be prepared in relation to the relevant literature, made 
available through an internet search. This literature will be referenced and acknowledged 
with the audit.  
Apart from the primary purpose of this audit project, it is hoped that the findings will also 
contribute to future decision-making in the Combined RT-Gynaecology Clinic. 
Dr. Kellie Alleyne-Mike 
Division of Radiation Oncology 
L-Block 
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PART B: STRUCTURED LITERATURE REVIEW: 
OBJECTIVES OF THIS  LITERATURE REVIEW: 
The objectives of this review are to provide the reader with the background and justification 
for the research, to describe the work already done in this field, and then to collate this 
information so as to evaluate and establish its relevance. Analysis may help to identify areas 
where further study is needed. 
Marshall and Rossman (1999) have stated that a discussion of related literature “builds a
logical framework for research and sets it within a tradition of enquiry and a context of
related studies”. Research is about contributing to a knowledge base; knowing what others
have done and discovered is an important first step towards formulating the research
question. Whilst one has to be cautious of the extent to which one’s research simply
replicates that of previous investigators, the literature review could, in the opinion of this
writer, play a confirmatory role in quantitative research by strengthening an evidence base. 
LITERATURE RESEARCH STRATEGY: 
This literature review was conducted by utilising searches of Science Direct, EBSCO, The
Cochrane Library, Google Scholar and PubMed, provided through the University of Cape
Town library resources. The search strategy employed keywords related to treatment of
“bulky early cervical cancer” and stage IB2 cervical cancer. Review of the relevant abstracts
identified by the search was first undertaken and, subsequently, the full article publications 
were assessed. Articles were chosen, based on relevance to the topic and the level of
evidence.
In the hierarchy of evidence generally accepted in clinical and other scientific research, meta-
analyses are deemed to occupy the highest tier. However, evidence based medicine further 
includes information from randomised controlled trials (RCT’s) which carry relatively more 
weight when compared to cohort, case-control, or cross-sectional studies. Many peer-
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INTRODUCTION TO THE LITERATURE REVIEW FOR THIS STUDY  
The treatment of cervical carcinoma is generally based on the disease stage however, there 
are other determinants which influence the choice of therapy such as the tumour volume and 
extent within a specific stage, availability of treatment modalities, therapeutic skills, patient 
preference, co-morbidities and the performance status of the patient.  The subdivision of 
stage IB (macroscopic tumour confined to the cervix) into IB1 and IB2 was recommended in 
1995: stage IB1 tumors are ≤4 cm in diameter, and stage IB2 tumours are ˃4 cm. This 
subdivision addresses the issue of tumour bulk within a stage IB, taking into account that 
patients with large stage IB tumors may have a worse prognosis and a greater tendency for 
lymph node mestastasis (Creasman 1995).  
For stage IB2, patients are treated with either primary surgery in the form of radical 
hysterectomy, with or without adjuvant radiotherapy, or primary radiation therapy (RT), 
with or without additional hysterectomy. It should be noted that for the past decade, both 
adjuvant and primary radiotherapy are delivered concurrently with cisplatinum-based 
chemotherapy. In this report, such concurrent chemo-radiation is abbreviated as CRT.  
The current study explores the treatment methods and outcomes of stage IB2 cervical cancer 
patients managed at Groote Schuur Hospital between the years 1993-2008.  Many reports 
have been published in the past, mostly as single institution retrospective series, exploring the 
management of “bulky” stage I cervical cancer.  In order to interpret and discuss the results 
of the current study, a survey of the available literature was conducted and the pertinent areas 
of interest were: 
 a)  relative effectiveness of surgery versus RT as primary treatment for stage IB2 cervical 
      cancer;    
 b)  definition of adverse prognostic features in post-operative series; 
 c)  preoperative factors and biological factors assessed during treatment; 
 d) effectiveness of adjuvant RT (or CRT), after primary surgery; 
 e)  retrospective studies of stage IB2 cervical cancer; 
 f)  utilising reduced pelvic volume (RPV) adjuvant radiation in node-negative patients; 
 g)   relative cost-effectiveness of the two primary modalities in stage IB2 cervical cancer; 
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LITERATURE REVIEW: 
a) Relative effectiveness of Radiation versus Surgery:
The merits of primary surgery include pathologic assessment of the extent of the disease, the 
preservation of ovarian and vaginal function and a shorter treatment time if used as a single
modality. However, two treatment modalities are often required. Primary CRT usually does
not require adjuvant treatment but the duration of the treatment course is longer and there is a
risk for delayed toxicity (Ackerman 2004; Moore 2003). In our study the criteria for salvage
hysterectomy following primary CRT included patients who had histological confirmation of
disease recurrence within 4 months of completing RT. Thus patients presenting with relapse
subsequent to this were not considered as requring dual modality as part of their primary
treatment. An early study of the efficacy of surgery versus RT in stage I cervical cancer was
reported by Morley and Seski (cited by Moore, 2003). They compared 208 women receiving 
radical hysterectomy with 193 women treated with pelvic irradiation and brachytherapy
between 1945-1975. The methodology was stated as a “modified alternating series”. The
corrected survival rates at five years were 87.3% for surgery versus 91.3% for RT, with
similar complication rates. Similar results were published by Volterrani and Feltre in 1983 in
a retrospective study of 250 patients with stage I cervical cancer. Disease-free survival at five
years was 90.9% and 89.3% for surgery versus RT, respectively. These early reports were
important in adding knowledge about what constitutes best practice in early cervical cancer. 
An important RCT in early cervical cancer was reported by Landoni and co-workers in 1997.
Most of the 337 patients enrolled in the trial had squamous pathology. Of note, 32% of the 
patients had tumours greater than 4 cm in both the surgical and the RT arms. Adjuvant RT 
was performed in 84% of the surgical cases if the tumour was >4 cm, versus 54% for smaller
tumours. Apart from the adequate sample size, a further strength of the study was a median
follow-up of 84 months. The five year actuarial overall survival rate was shown to be
statistically similar in both the treatment groups: 83% for surgery and 74% for RT. An equal
proportion of women in both groups developed recurrence (25% and 26% in the surgical and
radiotherapy arms, respectively). The authors concluded that there was no difference in 
outcome with regard to primary treatment modality for squamous carcinoma; however, more
patients in the surgery group experienced serious treatment-related morbidity (28%, versus 12
% in the RT group).  
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Decision-making for adjuvant therapy depends on the identification of histopathological 
factors which denote recurrence risk.  
Two Gynaecology Oncology Group (GOG) studies examined the influence of 
histopathological factors in surgically treated stage IB squamous carcinoma. Histological 
grade did not predict for nodal spread or DFI but increasing stromal invasion and, to a lesser 
extent, (LVSI) were predictive (Delgado et al., 1990). In another report, reviewing surgically 
treated patients who were node negative, a score was devised based on the presence of LVSI, 
the depth of stromal invasion, and tumour size. A “GOG score” of 120 or larger was 
associated with a 3-year DFI of around 60%, which may warrant adjuvant RT (Delgado et al., 
1989).  
Subsequent GOG studies examined the role of adjuvant therapy in stage IB cervical cancer, 
in which the following risk categories were proposed: 
1) High-risk: the presence of positive nodes, parametria and/or resection lines (Peters et al., 
2000). 
2) Intermediate-risk:
 Presence of LVSI plus deep third cervical stromal invasion and tumour of any size.
 Presence of LVSI plus middle third stromal invasion and tumour size ≥2 cm.
 Presence of LVSI plus superficial third stromal invasion and tumour size ≥5 cm.
 No LVSI but deep or middle one-third stromal invasion and tumour size ≥4 cm
(Sedlis et al., 1999).
Low-risk denotes the absence of the above factors. 
The issue of “close” resection margins has not been specifically defined in GOG studies.  
Resection margin status after radical hysterectomy in stage IB cervical cancer was assessed 
by Viswanathan and co-workers (2006), who concluded that post-operative radiation therapy 
may decrease local recurrence in patients with “close” (> 0 but < 10 mm) para-cervical 
margins.  Their study showed that the addition of adjuvant radiation therapy improved 
relapse-free survival (RFS) in all margin groupings, although the authors were cautious to 
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Biewenga et al. (2009) have reviewed 12 published prognostic models which purport to 
predict survival and recurrence in early stage cervical cancer. These models were 
retrospectively applied to a group of 512 patients, and an analysis made of each model’s 
performance.  All models underestimated the recurrence-free survival or disease specific 
survival. Only two were well suited for use in the population being assessed. The authors 
concluded that the difference in performance was due to the degree of heterogeneity in the 
choice of risk factors in each model, and because the individual factors were all equally 
weighted.  
The use of established prognostic factors has proven to be valuable in aiding decision making 
regarding adjuvant treatment, but caution must be taken in the model chosen for a particular 
population.  
c) Pre-operative factors and biological factors assessed during treatment.
An important prospective study was carried out by Dunst et al (2003). This study identified
the haemoglobin level as a strong predictor of local response to radiation therapy (both pre-
treatment levels and those during treatment). Angiogenesis was also determined by
measuring the grade of vascularization which, if increased, along with poor tumour 
oxygenation, was found to have an adverse effect on local tumour control and survival.
Other pre-operative factors which affect the response to treatment of patients with cervical 
cancer have been identified by Lai et al (1999) in a retrospective series. Variables such as the
tumour stage (assessed by clinical examination), depth of stromal invasion (detected using 
magnetic resonance imaging), tumour de-differentiation, tumour size and DNA index
(evaluated by flow cytometry) were all independent predictors of outcome after multivariate
analysis was done. 
Apart from tumour size, none of these factors were evaluated in the present study. The 
influence of haemoglobin levels will be the subject of further study in our institution, since 
low haemoglobin levels can be managed in an effort to improve local response. The other 
biological factors, while valuable indicators of treatment outcome, are not yet in routine 
clinical usage.  
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Concurrent chemo-radiation is now considered to be the standard of care for cervical cancer, 
as opposed to radiation therapy alone. This view is based on information derived from five 
RCTs (Keys et al. 1999; Whitney et al. 1999; Rose et al. 1999; Peters et al. 2000; Eifel et al. 
2004). In addition, various meta-analyses have confirmed the superiority of CRT over RT 
alone in cervical cancer. Green et al. (2001) found an improvement in overall survival (OS) 
with both platinum (HR 0.70, p<0.0001) and non platinum based regimes (HR 0.81, p=0.20). 
Progression-free survival (PFS) was also better with chemo-radiation (HR 0.61, p < 0.0001). 
The authors concluded that the absolute benefit in OS was 16%, with a 12% benefit in PFS, 
and a reduction in risk of death of 31%. This meta-analysis also evaluated grade 3 and 4 
toxicities. Haematological toxicity was the most common adverse effect documented. Gastro-
intestinal tract (GIT) toxicities were more significant in the CRT treatment arm when 
compared to control: 9.4% versus 4.3% (p<0.0001).  
In 2010, the Cochrane Group in the United Kingdom reviewed 18 randomised clinical trials 
of CRT in cervical cancer. The hazard ratios for each stage were assessed and they showed a 
10% increase in the 5-year survival when compared to RT alone for stages IB to IIA, which 
has relevance for the current study.  
One subgroup of early cervical cancer requiring post-operative adjuvant therapy does not 
appear to have been examined in the context of CRT versus RT in the setting of a RCT. The 
GOG study of Sedlis and co-workers (1999) randomised 277 patients with intermediate-risk 
factors and stage IB disease who had undergone radical hysterectomy to adjuvant radiation 
therapy or to no further treatment. There was a statistically significant reduction in the risk of 
recurrence for patients who received adjuvant radiation therapy (p=0.008) but this was 
accompanied by a concomitant increase in grade 3 and 4 toxicities. 
The follow-up to this study, published in 2006 by Rotman and co-workers, reported a 
sustained improvement in progression-free survival at 12 years follow-up (p=0.009) along 
with a reduced recurrence risk (p=0.007). However, the authors noted that overall survival 
was not significantly different in the two arms after six years of follow-up (p=0.07). Death 
due to non-disease related causes was suggested as the rationale for this unexpected finding 
as only four patients in the radiation arm recurred after this period. They also suggested that 
the power of the study may not have been sufficient to portray the continued survival benefit.  
A benefit in OS was observed in patients with adenocarcinoma as opposed to squamous 
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intermediate-risk factors, the GOG has initiated a study of adjuvant CRT versus RT in this 
group (NCI 2010). 
Regarding adjuvant therapy in the high-risk group (positive margins, parametria, and/or 
pelvic lymph nodes), the study by Peters and colleagues demonstrated the benefit of CRT in 
this subset of patients. Patients were randomised to RT, or RT with four cycles of cisplatinum 
and 5-fluorouracil chemotherapy. The addition of concomitant chemotherapy improved both 
OS and DFI (Peters et al., 2000). 
The number of concomitant chemotherapy cycles also appears to be important. Nugent and
co-workers (2010) retrospectively evaluated the effect on OS and PFS of completing six
cycles of weekly cisplatinum concurrent with RT. Their study of 118 patients included stages
I to IV, including 34% IB2 patients. In multivariate analysis, the number of chemotherapy
cycles was shown to be independently predictive of survival. The dose of cisplatinum was 
40mg/m² weekly; patients receiving fewer than five cycles of chemotherapy had a reduced
survival benefit when compared with those receiving 5-6 cycles, thus suboptimal cumulative
dose of chemotherapy may impact negatively on survival. The full course of chemotherapy
was not given in cases of poor performance status, poor compliance and severe treatment
related side effects, among others. 
The role of adjuvant CRT delivered with intensity modulated radiation therapy (IMRT) is 
being investigated as an approach to improve the therapeutic ratio. Chen and co-workers
compared IMRT with conventional four field box CRT. Similar loco-regional control was
demonstrated with reduced acute and chronic GIT toxicities and acute GU toxicity (Chen et 
al. 2008).
Thus adjuvant treatment confers a survival benefit in certain subsets of patients. Concurrent 
CRT is the standard although its necessity in patients with only intermediate risk factors is 
still a question under investigation. Newer techniques such as IMRT may improve dose 
intensity to target regions while reducing normal tissue toxicity. 
e) Retrospective studies of stage IB2 cervical cancer:
Yessaian et al (2004) evaluated the indications for adjuvant therapy with CRT after radical 
hysterectomy in 58 patients with stage IB2 who had undergone radical hysterectomy. Using 
the aforementioned GOG histopathological criteria, they retrospectively identified groups of 
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should have received adjuvant treatment instead of the 36 actually treated. The authors 
suggest that this perhaps explains the overall survival at 62%. They also stress the importance 
of counseling patients with stage IB2 requesting primary surgery so that they are aware of the 
high probability of requiring adjuvant RT/CRT.    
In another retrospective, a single-institution study, the authors report on their experience with 
primary chemo-radiation in 49 patients with stage IB2 cervical cancer (Goksedef and co-
workers, 2009). The 3-year PFS and OS were 79% and 86% respectively. Follow-on 
hysterectomy was not used. The authors conclude that routine hysterectomy is not necessary 
after definitive primary CRT in stage IB2, since their results compare favourably with the 
CRT plus adjuvant hysterectomy arm of the GOG 123 study (Keys et al., 1999). 
In a 2008 retrospective study by Zivanovic et al., 47 patients with IB2 were treated either 
with surgery (57%) or RT/CRT (43%). The 3-year OS was 72% and 55%, respectively
(p=0,161). Patients with co-morbidities were more likely to be offered primary RT/CRT. 
Treatment-related toxicities were the highest for surgery plus adjuvant therapy when
compared to either of those two modalities alone due to the fact that almost two-thirds of
these patients received adjuvant treatment. 
Thus, definitive treatment with either surgery or RT/CRT appear to have comparable survival 
in stage IB2 cervical cancer. There appears to be greater toxicity in the surgery arm possibly
due to the significant proportion of patients requiring adjuvant treatment. Subsequent 
hysterectomy in the patients who were treated with definitive radiation therapy is not 
routinely required.
f) Utilizing RPV adjuvant radiation in node-negative patients:
With histological risk factors dictating a need for post-operative CRT in more than 50% of 
cases of stage IB2, it would be better to deliver the adjuvant CRT as safely as possible. In the 
node negative group, the predominant risk is of central recurrence, as opposed to node 
positive patients who tend to relapse loco-regionally and distally (Thomas & Dembo, 1991). 
Many institutions have been assessing the benefit using smaller radiation fields applied to the 
tumour bed only. The dimensions of the RPV at our institution are 8 x 8 x 8 cm, with the 
inferior border of the volume being 2 cm distal to the vaginal vault.  
Hong and co-workers (2002) used this approach in 228 patients who were node negative but 
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percent consisted of bulky tumours (>4 cm). Most patients had concurrent chemotherapy and 
brachytherapy. The authors found that there was an increase in upper pelvic relapse which 
did not have a significant effect on survival. There was reduced toxicity with the use of a 
RPV.  
Similarly, Ohara et al. (2004) attempted to reduce toxicity with the use of a RPV.  However, 
the focus of their study was the outcome with regard to treatment toxicity. They observed a 
general reduction in GIT adverse effects and leucopenias but conversely an increase in 
bladder toxicity in patients who were in the RPV arm, as opposed to the ‘whole pelvis’ arm. 
While the authors believed this bladder toxicity to be a side effect of the surgical procedure 
(since both arms received RT to the whole bladder), it remains difficult to explain.  
The potential for reduced toxicity is encouraging, though a RCT is required to validate the 
safety of this practice as regards recurrence patterns. 
g)  Relative cost-effectiveness of the two primary modalities in stage IB2 cervical cancer: 
Jewell et al. (2007) did an analysis on cost-effectiveness, comparing radical hysterectomy 
(RHYST) with tailored adjuvant CRT versus primary CRT. The main methodology was 
Markov state transition modeling. Data from previous literature reviews were used to factor 
in expected overall survival, and treatment related toxicities. Costing schemes were obtained 
from Medicare data.  Radical hysterectomy followed by tailored CRT was found to be the 
most cost-effective option. Survival superiority, the cost of managing treatment toxicity and 
the cost of palliative care, where necessary, was also factored in.  
In a second cost-effectiveness modeling exercise, Rocconi et al. (2005) chose a hypothetical 
cohort of 10,000 patients and randomised them to three treatment strategies of RHYST, 
primary CRT, Neoadjuvant chemotherapy (NACT) (followed by radical hysterectomy and 
tailored CRT). In each grouping, adjuvant treatment may have been employed, based on 
certain radiologic or pathologic findings.  Data from phase III trials were predominantly 
employed but, in some cases, it was necessary to utilise data from phase II studies. In a 
manner similar to the study by Jewell et al., risk and frequency of complications were 
accounted for in the analysis. RHYST (with or without adjuvant CRT) again provided the 
most cost-effective method of treatment. The “cost per cure” estimated for NACT and 
primary CRT was higher than RHYST. CRT was found to cure more patients but at a 
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cost to diagnose and treat complications was not included in their estimations (unlike the 
study by Jewell et al.). Another limitation was that the rate of adjuvant CRT after RHYST 
was estimated at only 40%. The authors do, however, comment that in sensitivity analysis, 
when 80% of patients having primary surgery received adjuvant CRT, RHYST still remained 
the most cost-effective treatment.  
It cannot be assumed that these study findings can be generalized to the South African 
situation; from a simplistic viewpoint, a bi-modality treatment (surgery plus adjuvant CRT) 
may or may not be more expensive than a single one (primary CRT), but it does consume 
more limited resources – surgical as well RT resources. 
h) NACT:
Another area of interest in the management of stage IB2 cervical cancer is neoadjuvant
chemotherapy. The combinations of therapy which can produce the best outcome are still
being investigated. The Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis
Collaboration of the Cochrane group reviewed 18 trials comparing NACT followed by RT,
with RT only (at that time 93% of the known randomised evidence). Patients receiving more
intense doses of cisplatinum, or receiving CT at least every fortnight, appeared to have a
superior survival. Their subsequent analysis compared NACT, followed by surgery, with RT
alone. Five trials, accounting for 97% of known randomised trials were compared. Again,
there appeared to be greater survival benefit in the NACT arm but the authors felt that the
data was not substantial enough due to the relatively small number of patients and the high 
degree of heterogeneity among the trials.  
More recently, an updated review from the Cochrane group (Rydzewska et al., 2010) 
compared NACT plus surgery, to surgery only, in patients with cervical cancer. Six RCTs 
were reviewed, enlisting just over 1000 women. Analysis of pathological responses to NACT 
showed a “significant decrease in adverse pathological findings”.  The PFS was significantly 
improved by the neoadjuvant approach (p=0.01). No benefit in OS was found, hence it 
remains unknown whether NACT offers an advance in the management of cervical cancer, 
whether for early or more advanced stages.   
A final impression is that a truly comprehensive approach to the management of cervical 
cancer in general, and stage IB2 in particular, is required, which should involve all the 
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1) Prevention: vaccination against the oncogenic strains of the HPV virus;
2) Screening: a recent article published by Everett et al. (2011) reviewed 38 trials
assessing the most effective method of encouraging women to undergo cervical
cancer screening. The authors concluded that ‘the incidence of cervical cancer is
reduced by 93.5%, 92.5%, 90.8%, 83.6% and 64.1% if women have screening every
year, every two years, every three years, every five years and every ten years’.
3) Efficacious treatment: for stage IB2, both primary surgery and radiation are feasible
therapeutic options. The most effective mode, or combinations thereof, still has to be
determined.
4) Minimise toxicity: the adverse effects of a particular treatment must be evaluated and 
the potential impact on a patient’s quality of life should be taken into account during
counselling of patients regarding options of therapy. A 2009 study by Hsu et al. 
compared surgery and radiation therapy in early cervical cancer. They found that a
different group of complications predominated in each treatment arm but that there
were few differences in long term quality of life for the two groups. 
5) Treatment cost: this is of particular importance in developing countries where the
reality of economic constraints can often influence access to appropriate treatment. A
treatment option which is economically feasible without undue compromise to patient
survival is warranted.
6) Patient preference: patients must be given sufficient facts to make informed decisions.  
The inherent risks in any procedure such as early menopause, effects on sexual
function and compromise of reproductive potential due to ovarian ablation (whether it
be surgical or secondary to radiation therapy) should be imparted. 
Areas for continued research include: 
- Direct comparison of primary CRT versus RHYST in a randomised controlled trial
would provide more definitive information to practitioners regarding the best mode of
treatment for stage IB2.
- Validation of prognostic models for our treatment population which can guide the
decision regarding adjuvant treatment.
- There is still ongoing research into NACT and its role in this particular stage of the
disease.
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           These will, in all probability, play a role in our future management of this disease. 
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A retrospective review of patients with stage 1B2 cervical cancer 
treated with radical radiation versus radical surgery as a primary 
modality 
K.R. Alleyne-Mike*, A.L. Van Wijk*, A. Hunter^ 
(*Division of Radiation Oncology, ^Radiobiology Section, Groote Schuur Hospital and University of Cape 
Town, Anzio Road, Observatory, Cape Town, South Africa) 
ABSTRACT: 
Objective: To review the efficacy of treatment modalities in patients with stage IB2 cervical 
cancer treated at Groote Schuur Hospital, Cape Town, South Africa. 
Materials and methods: This was a retrospective observational study of patients with stage
IB2 cervical cancer treated from 1993-2008 with either primary radiation therapy (RT), with 
or without follow-on hysterectomy, or primary surgery (with or without adjuvant RT). 
Weekly cisplatin given concurrently with RT was used since 2003. Patient outcomes and 
grade 3-4 treatment-related toxicities were recorded. 
Results: The study included 78 eligible patients for whom the 5-year overall survival rate was 
70.8%. Overall 5-year survival rate by treatment modality was 88% for the 25 patients in the 
surgery group and 62.5% for the 53 patients in the RT group, respectively. There was a
marked difference in the proportion of patients in each group receiving additional therapy:
88% of patients in the primary surgery group had adjuvant RT, while only 5.7% of patients in 
the primary RT group went on to have a hysterectomy. Grade 3-4 toxicity was found in
13.2% of the RT versus 4% for the surgery group (p=0.4).
Conclusion: The optimal primary treatment for stage IB2 cervical cancer remains unclear.
Both types of primary treatments were found to be feasible therapeutic approaches. Primary
surgery appears to have better survival outcomes at our institution. Selection bias and 
inadequate concurrent chemotherapy in 58% of patients receiving primary RT may account
for the difference in survival. 
The number of patients in the surgery group requiring “bimodal” adjuvant treatment has cost 
implications in our resource-constrained environment, hence primary concurrent chemo-
radiation is being increasingly utilized for stage IB2 cervical cancer at our institution. 
Evidence from a randomized controlled study is needed to determine the optimal treatment 
for stage IB2 cervical cancer.   
Key words: cervical cancer, stage IB2, surgery, radiotherapy. 
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INTRODUCTION:  
In many developing countries, including South Africa, cervical cancer is one of the most 
common female cancers.
1
 Treatment for cervical cancer is relatively well defined for most 
stages, however, for stage IB2 there are no clear guidelines as to the best single treatment 
approach. Either primary surgery or radiotherapy (RT) is considered to be feasible. The 
merits of primary surgery include pathologic assessment of the extent of disease and 
preservation of ovarian and vaginal function. However, adjuvant treatment is more often 
required with primary surgery than with primary RT, which also carries a greater risk of 
delayed toxicity.
2 
The sub-classification of Stage IB cervical cancer recognizes that bulkier cervix-confined 
tumors may require different treatment approaches. The treatment of stage IB2 in our unit 
became biased towards primary RT because of concerns that adjuvant radiation may be 
frequently required if these bulky tumors were treated surgically. The consequences of such 
bimodal treatment include a protracted treatment course, increased costs for the patient and 
institution, and potentially increased treatment complications. 
This retrospective observational study was undertaken to evaluate local practice and outcome 
of patients with stage IB2 cervical cancer treated at Groote Schuur Hospital (GSH), Cape 
Town, South Africa, over a 16 year period (1993-2008). Permission to perform the data 
collection was obtained from the hospital management and the Human Research Ethics 
Committee of the Faculty of Health Sciences, University of Cape Town (Ref 129/2011).   
MATERIALS AND METHODS: 
Study setting: All patients referred with biopsy-positive cervical cancer were assessed at a 
weekly multi-disciplinary team (MDT) meeting. Staging of patients included a full blood 
count, renal and liver function tests, gynecologic pelvi-rectal examination, chest X-ray, 
ultrasonography of the renal tract and cystoscopy. Sigmoidoscopy was performed only where 
clinically indicated. More sophisticated radiological investigations for routine metastatic 
screening were not performed. 
Prior to the FIGO subdivision of stage IB in 1995, either one of the two therapeutic 
modalities of primary RT or surgery was prescribed for “bulky” IB cervical cancer, defined 
as tumors >4 cm in diameter.
3
 Patients with significant comorbidities and those with larger 
tumors were offered primary RT. Subsequent to 1995, there was selection pressure towards 
primary RT in an attempt to reduce bimodal treatment, though surgery was still offered to 
some patients with relatively smaller IB2 tumors.  
Primary RT doses to the pelvis varied between 40-56Gy (median 49.5Gy) over the study 
period and involved a four field box technique which covered the tumour bed and pelvic 
nodal regions up to the L5/S1 intervertebral space. Intracavitary brachytherapy was 
administered with low dose radium sources prior to 1994, and subsequently with fractionated 
high dose rate iridium therapy (5.0-7.5 Gy to Point A for four sessions). The other significant 
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cisplatinum with RT was introduced. The cisplatin dose was 40mg/m², with a maximum dose 
of 60mg per week, and a maximum of six weekly cycles. Following primary RT, patients 
were assessed after three months for extrafacial hysterectomy if histologic signs of tumor 
persistence were found. 
Primary surgery involved a Piver type 2 radical hysterectomy and bilateral pelvic 
lymphadenectomy. Decisions about post-operative therapy were taken at the weekly MDT 
review. The indications for adjuvant RT included: positive pelvic lymph node(s); close (<5 
mm) or involved resection lines; histological parametrial invasion; or Gynecologic Oncology
Group (GOG) score of  120 (product of relative risks for various tumor sizes, depths of
invasion, and presence or absence of lymphatic space invasion).
4
The adjuvant RT portals 
covered the whole pelvis. Variations in the adjuvant radiation technique included: a) reduced
pelvic volume (RPV) radiation in node-negative patients, since the volume at risk for
recurrence was considered to be the cervical tumor bed, or b) extended field radiation in 
patients with multiple positive pelvic and/or para-aortic lymph nodes. The dimensions of the
RPV were 8 x 8 x 8 cm, with the inferior border of the volume being 2 cm distal to the
vaginal vault. Vault brachytherapy was added if the vaginal resection lines were
compromised.
Patients were followed up at 3-monthly intervals for a year, thereafter at longer intervals.
Investigations were prompted by clinical suspicion.
Study methodology: A list of patients with stage IB2 cervical carcinoma treated between the
years 1993 and 2008 was retrieved from the Gyn-Oncology database at GSH. Patients 
diagnosed with Stage IB >4 cm in diameter before 1995 were assigned retrospectively to
stage IB2.  
Patients were grouped into the two treatment approaches of primary surgery and primary RT.
Each approach could become “bimodal” if adjunctive therapy was given. Hysterectomy after
RT was defined as bimodal if it was performed within four months of completing RT. 
Surgery beyond this period was considered to be “salvage” and was not included in the
analysis.
The inclusion criteria for this study were: 
 clinically staged 1B2 cervical cancer of histological subtypes: squamous,
adenosquamous or adenocarcinoma variety;
 in the primary radiation group, an external beam dose to the whole pelvis of at least
40 Gy, plus brachytherapy;
 in the primary surgery group, a completed radical hysterectomy and pelvic
lymphadenectomy (complete or partial nodal dissection);
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 absence of concurrent malignancies (except non-melanoma skin cancers) or previous 
pelvic irradiation 
Data collected included patient demographics, treatment modalities applied, response to 
treatment, and disease status on follow-up. Treatment-related morbidities experienced 90 
days or more after the completion of the treatment were considered to be late toxicities and 
graded according to the Radiation Therapy Oncology Group (RTOG) toxicity scores.
5
 Only 
grade 3 and 4 toxicities for gastrointestinal tract (GIT), bladder, and bone were documented. 
Follow-up was truncated at five years. Patients were censored at last follow-up or at time of 
death.  
Statistical calculations were made using Prism Graph pad (version 5.00; Graphpad software
R
, 
San Diego, Cal) and Epi Info (version 7; CDC, Atlanta, USA). Overall survival (OS) was 
defined as the time from treatment initiation until last follow-up or death. The 5-year OS rate 
was estimated using the Kaplan-Meier method, and the log rank test was performed to 
compare groups. The means of two groups were compared with the student t-test for 
continuous data, and with the chi-squared test for categorical variables.  
RESULTS: 
A total of 98 patients with stage IB2 were identified for the selected 16 year period from 
1993 to 2008. Of these, 78 patients met the inclusion criteria. Twenty patients were excluded 
(Figure 1). 
The median follow-up period was 59 months (6-60 months). The basic characteristics of the 
study population are shown in Table 1. Figure 1 demonstrates that 25 of the 78 patients 
(32.1%) underwent primary surgery and, of these, 22 (88%) went on to have adjuvant RT. 
Ten patients received RT to the whole pelvis and one received extended field RT. In 11 node-
negative patients, a RPV was irradiated. Figure 2 illustrates the indications for adjuvant 
therapy.  
In the primary surgical group, 3 patients of the 25 patients (12%) relapsed (Table 2). Of the 
two loco-regional relapses (8%), one patient with an adenocarcinoma received adjuvant RT 
with a RPV and relapsed with an ovarian metastasis 21 months later. This metastasis was 
outside the irradiation volume.   
The 5-year OS rate of the primary surgery group was 88%, which was significantly better 
than the 62.5% for primary RT (p = 0.03 - Figure 3A). 
The primary RT group comprised 53 patients (67.9%), of whom only three underwent 
additional treatment with hysterectomy (5.7%). Of the 53 patients in this group, 58% had 0-3 
cycles of concurrent weekly cisplatinum. The remainder received 4-6 cycles, with 
comparable survival to the primary surgery group (Figure 3B). Thirteen (24.5%) of the 
primary RT patients experienced a recurrence, 6 of whom had a component of loco-regional 
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Late treatment toxicity of RTOG grade 3-4 severity was seen in 4% of patients in the primary 
surgery group and 13.2% in the primary RT group, but this difference was not significant 
(p=0.4). None of the grade 3 or 4 complications occurred in the RPV adjuvant group.  
Table 3 illustrates univariate analysis of 5 year OS. 
DISCUSSION: 
This study records the treatment methods and outcomes of 78 patients with stage IB2 cervical 
cancer at GSH between 1993 and 2008. Patients were included if they presented with the 
common histological varieties, had completed curative treatment and had at least one year of 
follow-up. 
This study shows that 88% of the surgical cohort received post-operative RT, and although
the number of patients was relatively small, there was no apparent increase in complications
over primary RT. There was also an indication of better survival in the surgical group
(Figure 3B). It is necessary to examine further the relative merits of each treatment.
Previous unrandomized studies have shown that surgery and RT yield similar outcomes in
stage IB cancer, with 5-year survival between 80-90% for both modalities.
6,7
A landmark 
study was reported in 1997 by Landoni and colleagues
8
, in which 343 patients with stage IB-
IIA cervical carcinoma were randomized between radical hysterectomy versus radiation 
therapy. After a median follow-up of 87 months, the 5-year OS and disease free rates were
similar in both groups (for all patients, the OS was 83% and disease free interval was 74%). 
However, significantly greater treatment related morbidity was noted in the surgery arm
compared with the RT arm, irrespective of cervical diameter.
Of relevance for the current study is that Landoni et al.
8
found that approximately a third of
the patients in each arm had cervical diameter > 4 cm. Post-operative radiotherapy was
delivered in 84% of such patients, in contrast to 54% of patients with smaller tumors. In the 
subsets of patients with cervical diameter > 4 cm, pelvic relapse was significantly higher in 
the RT group than in the high-risk surgical + RT group (70% versus 53% of relapses). These
authors recommended that primary surgery should be reserved for those patients less likely to
need adjuvant treatment. 
Whether adjuvant treatment is required in surgically treated IB2 cervical cancer depends on 
the selection of histological factors known to predict for pelvic relapse. The GOG has 
established the following risk categories from its earlier studies:  
- High: positive nodes, parametria and/or resection lines9;
- Intermediate: negative lymphovascular space invasion (LVSI),  two-thirds depth of
cervical stromal invasion (CSI) and tumor >4cm; or positive LVSI, deep CSI and
tumor of any size; or positive LVSI, middle third CSI and tumor >2cm; or superficial
third CSI and tumor > 5cm
10
 ;
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In 2008, Zivanovic and co-workers
11
 reported on the treatment patterns of 47 patients with 
stage IB2 cervical cancer at their institution: 57% underwent primary surgery and 43% had 
RT. Overall, 52% of the primary surgery cases received adjuvant RT, while only 10% of the 
RT group underwent adjuvant simple hysterectomy (88% versus 5.7%, respectively, in the 
current study). In that study, the 3-year overall survival rates were 72% and 55% for primary 
surgery versus RT, respectively (p=0.161). Complication rates were comparable. 
Significantly more patients selected for RT had poorer anaesthetic risk factors and larger 
tumor size (median 6.1 cm, versus 5.1 cm for surgery). The authors conclude that while both 
modalities are feasible strategies for Stage IB2, the low rate of adjuvant radiation may be due 
to the presence of suspected nodal involvement on pre-operative imaging favouring selection 
towards RT. 
A primary surgical approach was described in 2004 by Yessaian and colleagues
12
.  Adjuvant 
RT was administered in 62% of 58 patients with stage IB2 cervical cancer. The 5-year OS 
was 62%. According to the current GOG risk criteria, 88% of their patients should have 
received adjuvant RT. These risk criteria were also applied retrospectively to a cohort of 72 
Stage IB2 patients by Havrilesky et al.
13
 “Tailored” adjuvant RT was applied only to 31% of 
patients:  in 0%, 12% and 94% of the low, intermediate, and high-risk groups, respectively. 
The current GOG criteria predict that 92% of all their patients should have received adjuvant 
RT. Five-year OS were 100% (low-risk), 80% (intermediate-risk) and 47% (high-risk). These 
authors warn that if the GOG criteria are to be followed, patients offered primary surgery 
need to understand that there is a significant chance of requiring adjuvant RT.  
Kamelle and co-workers retrospectively identified 86 patients with stage IB2 who had 
undergone radical surgery.
14
 Overall, 52% of their patients received adjuvant radiation: all the 
high-risk patients, none of the low-risk group, and only 31% of the intermediate-risk group. 
In the latter, there was no significant difference in disease-free interval (DFI) whether 
adjuvant therapy was given or not. Notably, those intermediate-risk patients without LVSI 
had a DFI of 97%. The authors suggest that the traditional GOG criteria may exaggerate risk 
in the intermediate group, particularly in those with negative LVSI, who could be treated with 
surgery alone. However, the median follow-up in this study was only 25 months.  
Monk and Koh
15
 have stressed that if the established GOG risk criteria are adhered to, 90% 
of patients with stage IB2 lesions treated with radical surgery may require adjuvant chemo-
radiation. Concurrent chemo-radiation has become standard practice in seemingly all stages 
of cervical cancer
16
, thought it has never been directly compared with RT alone within the 
context of a randomized study in the GOG intermediate-risk group. To address this issue, 
such a trial is currently being conducted.
17
 
In the node negative group, the predominant risk is for central recurrence; in contrast, node 
positive patients tend to relapse regionally or distally.
18
 Hong and co-workers
19
 
retrospectively analyzed responses of patients with histologically proven node negative 
cervical cancer stages I to IIA, who had received either whole pelvic RT, or RT to a RPV. 
Adjuvant radiation with a RPV reduced the incidence and severity of small bowel 
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though the safety and effectiveness of RPV versus traditional adjuvant RT have not been 
subjected to comparison in the setting of a RCT. In the current study, a RPV was 
administered to half the patients receiving adjuvant RT. None of these patients exhibited 
treatment complications. However, while such an approach theoretically reduces the risk of 
toxicity, the costs of dual therapy remain unchanged. 
Concerning post-operative risk stratification from prognostic models, a recent study was 
reported by Biewenga and colleagues (2011)
21
. Altogether 11 clinical and histological factors 
were examined in 710 patients who had surgery for early cervical cancer. A score chart was 
derived by multivariate Cox regression modelling and other statistical tools. While the main 
purpose of such a model would be to select and stratify patients for RCTs, this new tool could 
be applied to our stage IB2 patients in the future to reduce the numbers requiring adjuvant 
RT. Caution is needed, however, since this model has not been externally validated and the 
effect on survival of reducing indications for adjuvant therapy is unknown. 
Primary surgery plus adjuvant chemo-radiation appears intuitively more expensive than 
primary RT alone, though a direct cost-effectiveness comparison has never been done at our 
institution. Jewell and co-workers
22
 have estimated the relative cost-effectiveness of the two 
treatment approaches in stage IB2. Primary surgery plus tailored adjuvant RT was more 
expensive than primary RT ($27 800 versus $21 400) but depended strongly on the level of 
recommendation for adjuvant therapy. While it may not be accurate to generalize between 
institutions, this economic modelling confirms that bimodality treatment is more costly.  
In the present study, there was no significant difference in grade 3-4 late treatment related 
toxicities observed between the primary RT and surgery groups (crude rate 13.2% versus 4%,  
p=0.4). There was, however, a poorer 5-year OS for the primary RT group of 62.5%, versus 
88% for the surgical group (p=0,03). Various confounding factors could account for the 
worse outcome in the RT cohort. The larger median tumor size of 5.5 cm (versus 5.0 cm for 
the primary surgery group, Table 1) and worse survival of larger tumors on univariate 
analysis (p=0.01, Table 3), indicate a selection bias. The number of chemotherapy cycles 
given concurrently with radiation was also shown to have a significant impact on survival 
(Figure 3B), an observation which was also described by Nugent et al.
23
 The 58% of patients 
receiving 0-3 weekly cycles in our small series showed inferior survival to the remainder who 
received 4-6 cycles.  
Few patients undergoing primary RT require bimodal therapy. Routine hysterectomy after RT 
is unnecessary.
24
 Nijhuis et al
25
 have found that a gynecologic examination under anaesthesia 
was able to identify patients who had residual disease post-RT and who would be eligible for 
follow-on hysterectomy, so that only those likely to benefit are identified. Only 5.7% of the 
patients in our primary RT group underwent extrafacial hysterectomy for tumour persistence. 
Since the best therapy for stage IB2 is currently unknown, potential improvements in our 
management could include performing MRI pre-operatively to optimize the selection of 
patients for surgery, and PET-CT to detect metastatic disease, or residual cancer post-RT. 
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CONCLUSION: 
There are many limitations inherent to observational studies conducted retrospectively at a 
single institution, including selection bias, small patient numbers and deficiencies in 
individual patient data quality. Nevertheless, the current study suggests that both primary 
surgery and primary RT are feasible modalities in the management of stage IB2 cervical 
cancer at GSH. The observed trend of poorer survival outcome with primary RT may have 
resulted from the influences of treatment selection as well as both unmeasured and known 
covariates, such as tumor size and the number of chemotherapy cycles. 
In the surgical group, the use of tailored post-operative RT was well tolerated and safe, 
although ongoing concern about cost requires that the threshold for adjuvant RT be reviewed. 
In our resource-constrained environment, primary RT (with adequate concomitant cisplatin-
based chemotherapy) is increasingly being utilised to avoid bimodal therapy. 
This retrospective study, while confirming feasibility of the available modalities, does not 
inform the optimal approach for stage IB2 cervical cancer. A randomized controlled study of
the two treatment modalities is required. Ideally a third arm of neo-adjuvant chemotherapy
followed by surgery or RT should be included in such a study, along with measurement of
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TABLES AND FIGURES: 
FIGURE 1: A flow distribution of the number of patients treated, the proportions requiring 
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TABLE 1: Demographics and association between treatment modalities. 
VARIABLE ALL PATIENTS PRIMARY 
SURGERY 
PRIMARY RT P VALUE 
N (%) 78 (100%) 25 (32.1%) 53 (67.9%) 
Race: 
   Black 
   Coloured 
   White   
29 (37.2%) 
44 (56.4%) 
5 ( 6.4% ) 
11 (44%) 
12 (48%) 
2 ( 8% ) 
18 (34.0%) 
32 (60.4%) 
3 ( 5.7% ) 
Age: 
   Mean 45.6 47.1 ( SD 10.43) 44.8 (SD 10.69) 0.36
t
Histology: 
   Squamous 






6 ( 11.3%) 
0.07
c
Tumor size (cm): 
   Range 
   Median (Med) 
Median (>4 - <5) 















c- P values were obtained using the chi-squared test













~ 38 ~ 
FIGURE 2: The distribution of post-operative indications for RT in the primary surgical 
group. 
^ 
Close margins: 17 patients    
~
Positive margins: 3 patients 
*
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TABLE 2: Rates of toxicity, disease  progression and death 
% Primary 
 RT 






(n=78) of tot=78 ) 
Recurrence: 24.5   12.0 20.5 
    Loco-regional   9.4   8.0 9.0 
    Distant  13.2   4.0 10.3 
    Both local and distant   1.9   - 1.3 
Progression   1.9   - 1.3 
Partial response   5.7   - 3.8 
Vital status: 
   Alive disease free 62.3 84.0 69.2 
   Alive with disease   1.9   4.0 2.6 
   Death: from disease 30.2   8.0 23.1 
   Death: related to treatment         1.9   - 1.3 
   Death: other cause   3.8   4 3.8 
Toxicity: 
     Gastrointestinal   3.8*   4 4.9
     Bladder   9.4*   - 6.4 
     Bone   1.9   - 1.3 













~ 40 ~ 
FIGURE 3: Kaplan Meier curves illustrating overall survival trends in the different groups. 
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TABLE 3: Univariate analysis of 5-year overall survival. 
 











ALL GROUPS 78 70.8%   
AGE AT DIAGNOSIS 
     < 45 







0.75 1.14 (0.49 - 2.66) 
TUMOR DIAMETER 
(CM) 
     median <(5cm) 

















     Squamous 







0.28 1.83 (0.61 - 5.47) 
TREATMENT 
MODALITY 
      Primary Surgery 
      Primary RT (overall) 
 
No. of chemo cycles: 
     Primary RT (0-3 cycles) 
     Primary RT (4-6 cycles) 


































P value was obtained using the Log-rank test. 
a- Primary Surgery vs Primary RT (overall) 
b- Primary Surgery vs Primary RT (0-3 cycles of concurrent cisplatin)  
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APPENDICES: 





Age at Diagnosis 
Race         Black(B) Coloured(C)       White(W) 
Date of Registration 
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EBRT (External Beam RT) 
 
E 







Individual  Patient Treatment: 
Tumor size: 
Initial Surgical arm: 
 
S only  
S + E  
S + E + B  
 
Initial post-surgical factors: (where applicable ) 
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Depth of stromal invasion (mm) 
Yes No 
Presence of LN Metastases 
Positive < 5 > 5




Radiation arm (where applicable): 
E + B 
E +B + C 
E + B + S 
E +B + C + S 
External Beam RT: 
given with chemo 1 
given without chemo 2 
Salvage surgery path (where applicable): 
Tumor (widest diam/cm) 
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 Positive < 5 > 5 
Adequacy of resection 
margins (mm) 
   
 
 pos neg unknown 
Lymphovasc invas.    
 





Response to primary treatment: 
CR Complete response  
PR Partial response  
NR No response  
PD Progressive disease  
NE Not evaluable  
 
Treatment related toxicities: 
 GIT Bladder Bone 
Grade 3    
























Type of relapse: 
Loco-Regional L central 
pelvic side wall 
Distant D 
Both L + D 
Not Applicable N 
Treatment or recurrence/relapse: 
S (surgery) 
C (chemo) 
E (external beam radiation therapy)
TLC (supportive care/symptom cotrol)
Current Patient Status: 
Alive disease free 
Alive with disease 
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Deceased Disease (D-dis) 
Treatment (D-Tr) 
Other (D-Oth) 
OS ( overall survival): 
Other info relevant to case: 
Incomplete treatment is described as falling under one or more of the following
categories:
1) External Beam RT of < 40Gy ID2
2) External beam treatment protracted by 3 weeks or more
3) Brachytherapy not given (in primary CRT patients)
4) Brachytherapy less than prescribed fraction no.
5) No attempt at pelvic lymph node dissection













~ 52 ~ 
II: OFFICIAL ETHICS APPROVAL LETTERS: 
t::S-IVERSlTY OF C\PE TO\,("N 
Human Research Ethics Committee 
Room E52-24 Groote Selluur Hospiml Old l'>lain Building 
Ob"ervatoJry7925 
14 March 2011 
HREC REF: 129/2011 
Dr K AJle'J'n<?Milke 
Iudiation Orteo,lo,O' 
LE.14 
Dcar D r :\tl(~r'" ,\ li,,, 
4066626 • Facsimile 
e~mai~ Shl)retra.,hJ"n;!S(r,~u(;U(.z. 
PROJECT TITLE: A RETROSPECTIVE REVIEW OF THE DIFFERENCES IN OUTCOME 
WITH PATIENTS WITH STAGE 1112 CERVICAL CANCER TREATED W1TH RADIATION 
VERSUS RADICAL SURGERY AS A PRIMARY MODALITY. 
for s111)mitting your of t !l"ald) Science;; f lumiHl Research 1 ~t1llC5 C )mnuttce 
It is fi pl,'ssl)" to mfmm you that the Ethics Committee has for""t!lyapproved t])",,; ;1bovt,~-111cmion",<i 
Approval is gtaored for ooe year nllrhe 30 March 2012, 
Pkas\," subnut: an antlll~l1 I'" >gr,,, 
submit a bti,;;'f SU1Umaty 
(I"I ISO! ,i,l if r-h .. > r~"c<\rch continues 
cOlupll"r thr wilhin Ihe aPI)fOval 
011t' 111e" 
Ple:n:sc tlnte that tl1i: o g<)llng cthlc:al conduct of the remains rhe 
Please quote the HREC REF in an v"''' «>r""p<>"de"ee. 
F,~tt;11 \'\-"id<: "\ssHt'an(X' >-.;umb\'r: r,\x·_ \00001637. 
Insrirution;tl Rt.'\il'w Hoard number: IRB0000193H 
H) 
Zlat(\ Pll'ast: 
we call duse 













~ 53 ~ 





Daie 31'" Jarmarj- 20!2 
2012 




Groote Schuur HOiipltal 
1925 
Dear Prol< Blockman, 
• Re: Audit ",v<,vv. 
Ilepanemcnl Van (j:('sondbeid 
lJe",urtm •• , "r H.,.ltb 
IS-b. {.,,,,,Moiln 
"A rel'ro!1pectnle fflview of the differences in outcome with with 
1b2 cancer treated with rediation versus radical surgery as a primary 
modality' 
wish to apply for permission to extend my of review< I have pr!wi()usljl 
g",nll.d approval ( May 2(11) to extend my from 
to approval 10 collecl data for the peniods 1993 1m 2008< 
As II will involve an audit of foldens only; will nol be 
coinlacled, cOI1I'ldentl,lliIy is nol an issue< I wtli also like 10 advise of a ch"I1'''' in 
Of Patients with IB2 Cervical Ca<nCtir tl"eal'edat 
I will 10 receive your a~!~~'~~,~~OI:;t~he:i~a:~mendment of the above mentioned 
Please let me know if any other is required< 
Thank you in advanCE," 
Radiation Oncol(lQY) 
Ons«r1'(1I,Orv. 7915 













~ 54 ~ 







































~ 56 ~ 
En<luirics Or K. Alle~ne·\li).;e 
Telephone (02 1) - 40-1-1261 
Fa.\ 
[·Il1;lil !..mlke II 1I yahoo. com 
Reference 
Date 3,Ilr-. la):!O II 
Dr. S. Patel 
Chief Medical Superintendent 
Clinical Directorate 
G45, OMS 
Groote Schuur Hospital 
Observatory 
7925 
Dear Dr Patel , 
D~I)allcmel1t "all Gcsondhcid 
Department of Health 
ISebe lezeMoilo 
• Re: Audit project: "A retrospective review of the differences in outcome with 
patients with stage 1 b2 cervical cancer treated with radiation versus radical 
surgery as a primary modality' 
I hereby wish to apply for permission to perform an audit study, of the above title , in the 
Radiation Oncology Department of this hospital. It is a requirement of the MMed degreel 
College exam (FRC Rad Onc.) 
It will involve an audit of radiotherapy folders only ; patients will not be contacted , hence 
confidentiality is not an issue. 
Our Departmental Research Committee has approved the study, as well as the 
Research Ethics Committee (REC Ref No: 12912011). I have included a copy of my 
study proposal for your perusal. 
I shall therefore be grateful to receive your approval, as the member of the Clinical 
Directorate responsible for research projects at Groote Schuur Hospital , to proceed with 
thiS study. Please let me know if any other documentation IS required 
Thanking you in anticipation 
Sincerely 
• /1 
/ I ~ 
Dr. K R Alleyne-Mike (Registrar, Dept Radiation Oncology) 
LE 33 Clinic 
.. , . 
~ 




Lnq ics D IIc)ne·\lilc
rd il llc t 4 -l f
I~·rnaj r I..r l.....: ii uu
dcrc l" 
;tl J".  M3  2U ll
. 



































~ 57 ~ 
RESEARCH: 1. Extension of Resecrch 
2. Rewording of lIe,ecrch to "A Retrospective Study O! Patients With Slage 
182 Cervical Cance, Treated At Groote Schuur Hospital B!!tw!!!!n 1993·2008" 
Your recent letler to tho ho'spital reters. 
You are "."",t", n,m,j",rl n"'m0~"M to extend and chana" the focus 01 your reseorch. 
Pleose note the fall'DwinQ: 
Your research may nallnlerfere with normal care 
Homitni staff may not be asked 10 assist the research. 
cJ No consumables and may be used. 
dl No palient folders may be removed from Ihe premise, or be Inaccessible. 
e) Please introduce te the persor: in of on oreo before rnmnnAind!1C1 
fJ Pleose discuss the with the Head of Rodiarion 
I would like to wish you every success with the prci;e,". 
DR IIHAVNA PATEL 
SENIOR MANAGER: MEDICAL SERVICES 













~ 58 ~ 
III: GUIDELINES TO AUTHORS (INTERNATIONAL JOURNAL OF 
GYNAECOLOGIC CANCER) 
Scope 
International Journal of Gynecological Cancer, the official journal of the International 
Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the 
primary educational and informational publication for topics relevant to detection, 
prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a 
multidisciplinary approach, and includes original research (clinical trials and translational or 
basic research), reviews, and opinion pieces. The audience consists of gynecologists, medical 
oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a 
special interest in gynecological oncology.  
Ethical/Legal Considerations
A submitted manuscript must be an original contribution not previously published (except as 
an abstract or a preliminary report), must not be under consideration for publication 
elsewhere, and, if accepted, must not be published elsewhere in similar form, in any
language, without the consent of Lippincott Williams & Wilkins. Each person listed as an 
author is expected to have participated in the study to a significant extent. Although the 
editors and referees make every effort to ensure the validity of published manuscripts, the
final responsibility rests with the authors, not with the Journal, its editors, or the publisher. 
All manuscripts must be submitted on-line through the journal’s Web site at 
http://igc.edmgr.com. See submission instructions under “On-line manuscript 
submission.” 
Patient anonymity and informed consent: It is the author’s responsibility to ensure that a
patient’s anonymity be carefully protected and to verify that any experimental investigation 
with human subjects reported in the manuscript was performed with informed consent and 
following all the guidelines for experimental investigation with human subjects required by
the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes 
and remove patients' names from figures unless they obtain written consent from the patients 
and submit written consent with the manuscript.
Copyright: All authors must sign a copy of the Journal’s “Authorship Responsibility, 
Financial Disclosure, and Copyright Transfer” form and submit it at the time of manuscript 
submission. 
Compliance with NIH and Other Research Funding Agency Accessibility Requirements: A 
number of research funding agencies now require or request authors to submit the post-print 
(the article after peer review and acceptance but not the final published article) to a repository 
that is accessible online by all without charge. As a service to our authors, LWW will identify 
to the National Library of Medicine (NLM) articles that require deposit and will transmit the 













~ 59 ~ 
of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to 
PubMed Central. The Copyright Transfer Agreement provides the mechanism. 
Permissions: 
For permission and/or rights to use content for which the copyright holder is LWW or the 
society, please go to the journal's website and after clicking on the relevant article, click on 
the "Request Permissions" link under the "Article Tools" box that appears on the right side of 
the page. Alternatively, send an e-mail to customercare@copyright.com. 
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, 
Licensing & Permissions Manager,  Wolters Kluwer Health (Medical Research) Ltd, 250 
Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail: 
silvia.serra@wolterskluwer.com 
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales, 
Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, 
PA 19103. Phone: 215-521-8638. E-mail: alan.moore@wolterskluwer.com
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations 
Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 
250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail:
silvia.serra@wolterskluwer.com
Manuscript Submission 
On-line manuscript submission: All manuscripts must be submitted on-line through the Web 
site at http://igc.edmgr.com.  
First-time users: Please click the Register button from the main menu and enter the 
requested information. On successful registration, you will be sent an e-mail indicating your 
user name and password. Print a copy of this information for future reference. Note: If you 
have received an e-mail from us with an assigned user ID and password, or if you are a repeat 
user, do not register again. Just log in. Once you have an assigned ID and password, you do 
not have to re-register, even if your status changes (that is, author, reviewer, or editor).  
Authors: Please click the log-in button from the menu at the top of the page and log in to the 
system as an Author. Submit your manuscript according to the author instructions. You will 













~ 60 ~ 
Preparation of Manuscript 
Manuscripts that do not adhere to the following instructions will be returned to the 
corresponding author for technical revision before undergoing peer review. 
Manuscripts should be no longer than 3000 words (not including the abstract and references). 
Title page: The title page must be submitted as a separate file. Include on the title page (a) 
complete manuscript title; (b) authors’ full names, highest academic degrees, and affiliations; 
(c) name and address for correspondence, including fax number, telephone number, and e-
mail address; (d) address for reprints if different from that of corresponding author; and (e)
all sources of support, including pharmaceutical and industry support, that require
acknowledgment.
The title page must also include disclosure of funding received for this work from any of the
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard 
Hughes Medical Institute (HHMI); and other(s). 
Structured Abstracts: Limit the abstract to 300 words. Do not cite references in the abstract. 
Limit the use of abbreviations and acronyms. Use the following headings: Objective, 
Methods/materials, Results, and Conclusions. List three to five key words. Examples of key
words: clear cell, cisplatin, ovarian carcinoma, ultrasound.
Text: Organize the manuscript into four main headings: Introduction, Materials and Methods, 
Results, and Discussion. Define abbreviations at first mention in text and in each table and 
figure. If a brand name is cited, supply the manufacturer's name and address (city and 
state/country).
Abbreviations: For a list of standard abbreviations, consult the Council of Biology Editors 
Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, 
MD 20814,www.councilscienceeditors.org) or other standard sources. Write out the full term 
for each abbreviation at its first use unless it is a standard unit of measure. 
References: The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance. Cite unpublished data—such as papers submitted but not yet accepted 
for publication and personal communications, including e-mail communications—in 
parentheses in the text. If there are more than three authors, name only the first three authors 
and then use et al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of 
journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html. There should 
be no more than 25 references. If there are more than 25, please limit the published references 
to 25 and insert the following sentence: “For the complete list of references, please contact 













~ 61 ~ 
Sample references are given below: 
Journal article 
1. Rand NS, Dawson JM, Juliao SF, et al. In vivo macrophage recruitment by murine
intervertebral disc cells. J Spinal Disord 2001;14:339--342.
Book chapter 
2. Todd VR. Visual information analysis: frame of reference for visual perception. In:
Kramer P, Hinojosa J, eds. Frames of Reference for Pediatric Occupational Therapy.
Philadelphia, PA: Lippincott Williams & Wilkins; 1999:205–256.
Entire book 
3. Kellman RM, Marentette LJ. Atlas of Craniomaxillofacial Fixation. Philadelphia, PA:
Lippincott Williams & Wilkins; 1999.
Software 
4. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and
Prevention; 1994.
Online journals 
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial 
online]. January 1988;71:22-37. Available from: BRS Information Technologies, McLean, 
VA. Accessed December 15, 1990.
Database 
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. 
Updated March 29, 1996.
World Wide Web 
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. 
Available at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997.
Figures: There should be no more than 6 graphics, including figures and tables. 
Digital art should be created/scanned and saved and submitted as either a TIFF (tagged image 
file format), an EPS (encapsulated postscript) file. PPT (Power Point) files will also be 
accepted. Electronic photographs—radiographs, CT scans, and so on—and scanned 
images must have a resolution of at least 300 dpi. Line art must have a resolution of at 
least 1200 dpi (dots per inch). If fonts are used in the artwork, they must be converted to 
paths or outlines or they must be embedded in the files. Color images must be 
created/scanned and saved and submitted as CMYK files. If you do not have the 
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that you are unable to produce CMYK files. Cite figures consecutively in the text, and 
number them in the order in which they are discussed.  
Detailed Figure Instructions: For a step by step guide for submitting Digital Art please visit 
www.LWWonline.com. Click “For Authors” and click “Artwork” and “5 Steps for 
Creating Digital Artwork” in the menu to the right.  
Figure legends: Include legends for all figures. They should be brief and specific, and they 
should appear on a separate manuscript page after the references. Use scale markers in the 
image for electron micrographs, and indicate the type of stain used. 
Color figures: The journal accepts for publication color figures that will enhance an article. 
Authors who submit color figures will receive an estimate of the cost for color reproduction. 
If they decide not to pay for color reproduction, they can request that the figures be converted 
to black and white at no charge. 
Tables: There should be no more than 6 graphics, including figures and tables.
Create tables using the table creating and editing feature of your word processing software
(eg, Word, WordPerfect). Do not use Excel or compar ble spreadsheet programs. Group all
tables in a separate file. Cite tables consecutively in the text, and number them in that order.
Each table should appear on a separate sheet and should include the table title, appropriate
column heads, and explanatory legends (including definitions of any abbreviations used). Do 
not embed tables within the body of the manuscript. They should be self-explanatory and 
should supplement, rather than duplicate, the material in the text.
Style: Pattern manuscript style after the American Medical Association Manual of Style (9th 
edition). Stedman’s Medical Dictionary (27th edition) and Merriam Webster’s Collegiate
Dictionary (10th edition) should be used as standard references. Refer to drugs and
therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. 
Use code numbers only when a generic name is not yet available. In that case, the chemical 
name and a figure giving the chemical structure of the drug is required. Copyright or trade
names of drugs should be capitalized and placed in parentheses after the name of the drug. 
Names and locations (city and state in USA; city and country outside USA) of manufacturers 
of drugs, supplies, or equipment cited in a manuscript are required to comply with trademark 
law and should be provided in parentheses. Units of measure should be expressed in the 
metric system, and temperatures should be expressed in degrees Celsius. Conventional units 
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Sections 
Original Articles: Our intent is to publish high quality research as it relates to clinical trials, 
outcome analyses, translational research, cost utility analyses, etc.  
Review Articles: Our intent is to include high quality review articles, of 2500 words and up to 
20 references, which will address a topic of major interest in the field of gynecologic 
oncology. 
Brief Reports: Articles having a maximum of 1500 words and an abstract with a highly 
focused message and minimum of methodological detail, and maximum of 15 references. 
Include "Brief Report: " in the title. 
Surgeon’s Corner: Intended to describe a specific issue of surgical technique that is rather
new of modified. This section is limited to 1000 words and up to 5 references and will be
peer reviewed.
Letters to the Editor: The Editorial Board reserves the right to decline publishing insulting or 
inflammatory comments in letters to the editor. Letters should be a short and concise 
communication commenting on a recently published article in the Journal or commenting on 
a controversial current issue of concern to the readership. A Letter to the Editor is not a site
for publication of original results. The letter should have no more than 3 authors and contain 
no more than 5 references, including a reference to the article in question. A statement of 
potential sources of conflict of interest must accompany the letter and may be published 
along with the letter.
Multimedia files 
Supplemental Digital Content 
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to 
LWW journals that enhance their article’s text to be considered for online posting.  SDC may 
include standard media such as text documents, graphs, audio, video, etc.  On the Attach Files 
page of the submission process, please select Supplemental Audio, Video, or Data for your 
uploaded file as the Submission Item.  If an article with SDC is accepted, our production staff 
will create a URL with the SDC file.  The URL will be placed in the call-out within the 
article.  SDC files are not copy-edited by LWW staff, they will be presented digitally as 














~ 64 ~ 
 SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript.  Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), be clearly labeled as “Supplemental Digital Content,” include the sequential list 
number, and provide a description of the supplemental content.  All descriptive text should be 
included in the call-out as it will not appear elsewhere in the article.  
Example: 
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.  
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript
file. Include the SDC number and file type of the Supplemental Digital Content. This text 
will be removed by our production staff and not be published.
Example: 
Supplemental Digital Content 1.  wmv 
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 
10 MBs, authors should first query the journal office for approval. For a list of all available 
file types and detailed instructions, please visit http://links.lww.com/A142. 
After Acceptance 
Page proofs and corrections: Corresponding authors will receive electronic page proofs to 
check the copyedited and typeset article before publication. Portable document format (PDF) 
files of the typeset pages and support documents (eg, reprint order form) will be sent to the 
corresponding author by e-mail. Complete instructions will be provided with the e-mail for 
downloading and printing the files and for faxing the corrected page proofs to the publisher. 
Those authors without an e-mail address will receive traditional page proofs. It is the author’s 
responsibility to ensure that there are no errors in the proofs. Changes that have been made to 
conform to journal style will stand if they do not alter the authors' meaning. Only the most 
critical changes to the accuracy of the content will be made. Changes that are stylistic or are a 
reworking of previously accepted material will be disallowed. The publisher reserves the 
right to deny any changes that do not affect the accuracy of the content. Authors may be 
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queries. Proofs must be checked carefully and corrections faxed within 24 to 48 hours of 
receipt, as requested in the cover letter accompanying the page proofs. 
Reprints: Authors will receive a reprint order form and a price list with the page proofs. 
Reprint requests should be faxed to the publisher with the corrected proofs, if possible. 
Reprints are normally shipped 6 to 8 weeks after publication of the issue in which the item 
appears. Contact the Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden 
Street, Baltimore, MD 21201; Fax: 410-528-4434; E-mail: reprints@wolterskluwer.com with 
any questions. 
Publisher's contact: Fax corrected page proofs, reprint order form, and any other related 
materials to Journal Production Editor, International Journal of Gynecological Cancer, 351 
W. Camden Street, Baltimore, MD 21201-2436; 410-528-4266 (fax).
